SBS-IF stands for short bowel syndrome with intestinal failure. People with SBS-IF are missing parts of their small intestine or colon mainly due to surgical removal of the intestine or the colon. Common causes of SBS-IF include:
With SBS-IF, the body can no longer maintain hydration or ability to absorb fluids or nutrition on its own. To maintain life, patients need artificial nutrition, known as parenteral support.
There are significant burdens that SBS-IF patients have when they need to live with their parenteral support. While it can be lifesaving, it can also significantly impact quality of life. By enrolling in this Phase 3 study, you may potentially see improved bowel (gut) function with better absorption of fluids and nutrition that leads to:
Are 18 years of age or older
Have diagnosis of SBS-IF and a stoma
Require 3 or more days a week of parenteral support such as TPN, IV fluids, or electrolytes
Receive parenteral support such as TPN, IV fluids, or electrolytes for more than 6 months
We know that every individual has a different experience with their SBS. By participating in this study, you will be seen by SBS experts and could receive specialized care for your SBS with the goal of improving overall gut function.
Click here to see if you may qualify.
Upon initial eligibility, a patient outreach representative will call you and help guide you through additional eligibility questions.
The team at a participating study center will determine if you are eligible to participate in the study and what would be required for participation.
Throughout the study, you will take the study medication weekly and have a mix of virtual and in-person visits, depending on your needs. You will be asked to keep a diary to record specific experiences and answer questions about your experience living with SBS-IF.
VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies tailored to patients’ needs. They are headquartered in Basel, Switzerland, with business operations in the New York area.